![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1479979
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå, ¿¹Ãø(-2029³â)Global Molecular Diagnostics Market, Forecast to 2029 |
ºÐÀÚÁø´ÜÀÌ ¼ºÀå ±âȸ¸¦ ºÒ·¯ÀÏÀ¸Å°°í, Çõ½ÅÀû ¸ÂÃãÇü ÀÇ·á·Î ³ª¾Æ°¥ ¼ö ÀÖ´Â ±æÀ» ¿¾î
¼¼°è ºÐÀÚÁø´Ü ½ÃÀåÀº COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¼ö¿ä Áõ°¡, ¾Ï ȯÀÚ Áõ°¡, ºü¸¥ ±â¼ú ¹ßÀü µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Å« ÆøÀÇ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR), µðÁöÅÐ PCR, Â÷¼¼´ë ¿°±â¼¿ºÐ¼®(NGS) µî ±â¼úÀÇ ¹ßÀüÀ¸·Î ºÐÀÚ °Ë»çÀÇ Á¤È®¼º°ú »ý»ê¼ºÀÌ Çâ»óµÇ¾î °³Àκ° ¸ÂÃã Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù.
¿¹Ãø ºÐ¼®Àº Áö¿ª°ú ¿ëµµº°·Î ±¸ºÐµË´Ï´Ù. ÈÄÀÚ´Â °¨¿° °Ë»ç, Á¾¾ç °Ë»ç, À¯ÀüÀÚ °Ë»ç ¹× ±âŸ ºÐÀÚÁø´ÜÀ» Æ÷ÇÔÇϸç, Frost & SullivanÀÇ ÀÌ »ê¾÷ ¿¹ÃøÀº ¹æ¹ý·ÐÀû Á¦¾àÀ¸·Î ÀÎÇØ ¼ºÀå ±âȸ ºÐ¼®¿¡ ÁúÀû Á¢±Ù ¹æ½ÄÀ» »ç¿ëÇÕ´Ï´Ù.
¾Ï ¹ßº´·üÀÇ Áõ°¡·Î ÀÎÇØ ÷´Ü ºÐÀÚÁø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ °¡¼Óȵǰí, ¸¸¼º ÁúȯÀÇ Áõ°¡, Á¤ºÎÀÇ ÀÇ·á Çö´ëÈ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ºÐÀÚÁø´Ü »ê¾÷ÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á ±ÔÁ¦ÀÇ °È¿Í R&D ÅõÀÚ È®´ë´Â ÀÌ·¯ÇÑ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Molecular Diagnostics Unleash Growth Opportunities, Steering Innovation Personalized Medicine
The global molecular diagnostic market will experience significant growth due to a broad range of factors, such as increased demand from the COVID-19 pandemic, an increasing number of cancer cases, and the swift evolution of technological capabilities.
Technological advancements, such as polymerase chain reaction (PCR), digital PCR, and next-generation sequencing (NGS), have improved molecular testing accuracy and productivity, enabling personalized treatment.
The forecast analysis is segmented by region and by application. The latter includes infectious disease testing, oncology testing, genetic testing, and other molecular diagnostics. Frost & Sullivan's forecasts for this industry use a qualitative approach for the growth opportunity analyses due to methodological constraints.
The growing prevalence of cancer has accelerated the need for advanced molecular diagnostic tools, while the rise in chronic diseases, the modernization of government healthcare, and the growing demand for personalized medicine will contribute to the significant growth anticipated in the molecular diagnostics industry. Focused healthcare regulations and substantial R&D investments facilitate this expansion.